

Express Mail Label No.: ELS 5398US  
Date of Deposit: October 10,

#7A  
See  
4/3/02



**PATENT APPLICATION**  
Attorney Docket No. 21486-047

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Wands et al  
SERIAL NUMBER: 09/872,968  
FILING DATE: June 1, 2001  
FOR: INHIBITION OF NEURODEGENERATION

EXAMINER: Not Yet Assigned  
ART UNIT: 1646

**BOX MISSING PARTS**

Assistant Commissioner for Patents  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Prior to examination of the above-identified patent application, please amend the application as set forth below and consider the following remarks.

*In the Specification:*

Please insert the Sequence Listing, pages 1-3, at the end of the specification.

**REMARKS**

Applicants submit a Sequence Listing for the nucleotide sequences disclosed in the specification, in compliance with the requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures. 37 C.F.R. §§ 1.821-1.825.

**CONCLUSION**

Applicants respectfully submit that the present application complies with 37 C.F.R. §§ 1.821-1.825. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

Ingrid A. Beattie, Reg. No. 42,306  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Dated: October 10, 2001